Amylyx Files for European Approval of AMX0035 in Treating ALS
Amylyx Pharmaceuticals has filed an application with the European Medicines Agency seeking the approval of its lead candidate AMX0035 as a treatment of amyotrophic lateral sclerosis (ALS), the company announced in a press release. The marketing authorization request follows similar submissions to Health Canada and the U.S. Food and Drug Administration. U.S. regulators recently […]
Amylyx Files for European Approval of AMX0035 in Treating ALS Read More »